Imperva Inc (NYSE:IMPV) had its price target increased by Monness Crespi & Hardt from $55.00 to $57.00 in a research report released on Friday, July 28th, Marketbeat Ratings reports. The firm currently has a buy rating on the software maker’s stock.
Several other research analysts have also commented on the company. ValuEngine lowered Imperva from a hold rating to a sell rating in a research report on Tuesday, July 11th. Evercore ISI reiterated a buy rating and issued a $56.00 price target on shares of Imperva in a research report on Friday, May 5th. Zacks Investment Research lowered Imperva from a buy rating to a hold rating in a research report on Tuesday, May 9th. TheStreet upgraded Imperva from a d rating to a c rating in a research report on Thursday, May 4th. Finally, Royal Bank Of Canada boosted their target price on Imperva from $52.00 to $55.00 and gave the company an outperform rating in a research report on Friday, May 5th. Two analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $51.25.
Shares of Imperva (IMPV) traded down 1.12% during midday trading on Friday, hitting $44.10. The stock had a trading volume of 379,391 shares. Imperva has a 52 week low of $34.40 and a 52 week high of $57.24. The company’s 50 day moving average is $47.18 and its 200 day moving average is $45.43. The firm’s market cap is $1.49 billion.
Imperva (NYSE:IMPV) last released its quarterly earnings results on Thursday, July 27th. The software maker reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by $0.15. The company had revenue of $74.44 million during the quarter, compared to analysts’ expectations of $74.30 million. Imperva had a negative return on equity of 5.00% and a negative net margin of 4.69%. The company’s revenue was up 28.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.23) EPS. On average, equities analysts predict that Imperva will post $0.81 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Monness Crespi & Hardt Increases Imperva Inc (IMPV) Price Target to $57.00” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://stocknewstimes.com/2017/08/17/imperva-inc-impv-given-new-57-00-price-target-at-monness-crespi-hardt-updated-updated.html.
Large investors have recently made changes to their positions in the stock. ETF Managers Group LLC bought a new stake in shares of Imperva during the second quarter worth $41,888,000. North Run Capital LP raised its stake in shares of Imperva by 999.3% in the first quarter. North Run Capital LP now owns 750,000 shares of the software maker’s stock worth $30,788,000 after buying an additional 681,772 shares during the period. Clearbridge Investments LLC raised its stake in shares of Imperva by 47.0% in the first quarter. Clearbridge Investments LLC now owns 1,262,507 shares of the software maker’s stock worth $51,826,000 after buying an additional 403,809 shares during the period. BlackRock Inc. raised its stake in shares of Imperva by 11.3% in the second quarter. BlackRock Inc. now owns 2,124,043 shares of the software maker’s stock worth $101,635,000 after buying an additional 215,170 shares during the period. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Imperva by 8,392.3% in the first quarter. BNP Paribas Arbitrage SA now owns 200,927 shares of the software maker’s stock worth $8,248,000 after buying an additional 198,561 shares during the period. 92.72% of the stock is currently owned by hedge funds and other institutional investors.
About Imperva
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with MarketBeat.com's FREE daily email newsletter.
